Lates News

According to the AI fast news, Huayuan Securities released a research report on March 23, giving Junshi Biosciences (688180.SH) a "buy" rating. The reasons for the rating include: 1) a well-known domestic innovative pharmaceutical company with a solid business foundation; 2) strong innovative pipeline strength, with the late-stage pipeline expected to gradually enter the realization period; 3) a differentiated early research pipeline with promising future prospects. (Daily Economic News)